Pfenex and Hospira to develop Lucentis biosimilar candidate
Clinical-stage biotechnology firm Pfenex has partnered with Hospira to develop and commercialise PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 11, 2015 Category: Pharmaceuticals Source Type: news
Lucentis Approved for Diabetic Retinopathy
Title: Lucentis Approved for Diabetic RetinopathyCategory: Health NewsCreated: 2/9/2015 12:00:00 AMLast Editorial Review: 2/10/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - February 10, 2015 Category: Endocrinology Source Type: news
Lucentis Approved for Diabetic Retinopathy
Among diabetics with macular edemaSource: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 9, 2015 Category: Consumer Health News Source Type: news
FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Media News)
Source: Roche Media News - February 9, 2015 Category: Pharmaceuticals Source Type: news
FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Investor Update)
Source: Roche Investor Update - February 9, 2015 Category: Pharmaceuticals Source Type: news
Ranibizumab Approved to Treat Diabetic Retinopathy (FREE)
By The Editors
The FDA has approved ranibizumab (Lucentis) to treat diabetic retinopathy in patients who have diabetic macular edema.Ranibizumab, previously … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 9, 2015 Category: Primary Care Source Type: news
FDA Clears Ranibizumab for Diabetic Retinopathy With DMEFDA Clears Ranibizumab for Diabetic Retinopathy With DME
Ranibizumab for diabetic retinopathy with DME had breakthrough therapy designation and was reviewed under the agency's priority review program. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2015 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema
The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 6, 2015 Category: American Health Source Type: news
FDA Okays VEGF Drug for Diabetic Retinopathy
(MedPage Today) -- Lucentis wins an indication in diabetic retinopathy. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2015 Category: Primary Care Source Type: news
Paid to Promote Eye Drug, and Prescribing It Widely
Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows. (Source: NYT Health)
Source: NYT Health - December 8, 2014 Category: Consumer Health News Authors: By KATIE THOMAS and RACHEL ABRAMS Tags: Medicare Lucentis (Drug) Doctors Roche Holding AG RHHBY Other OTC Macular Degeneration Genentech Inc Avastin (Drug) Source Type: news
NHS: Scandal of the sight saving drug doctors are not allowed to prescribe
Bill Organ’s sight was saved by injections of the drugs Avastin and Lucentis. Both drugs stop the loss of central vision caused by age-related macular degeneration (AMD). (Source: the Mail online | Health)
Source: the Mail online | Health - November 25, 2014 Category: Consumer Health News Source Type: news
Ranibizumab preferred option in myopic CNV
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2014 Category: Drugs & Pharmacology Source Type: news
Regeneron's Eylea Works Better vs Avastin and Lucentis in StudyRegeneron's Eylea Works Better vs Avastin and Lucentis in Study
Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 21, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2014 Category: Pharmaceuticals Source Type: news
Regeneron's Eylea works better vs Avastin and Lucentis in study
(Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis. (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
